ArticleJCO global oncology2020
Operational Strategies for Clinical Trials in Africa.
Article in JCO global oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Delays in seeking, reaching and access to quality cancer care in sub-Saharan Africa: a systematic review.BMJ open · 2023Pooled it
- Transition to psychosis in randomized clinical trials of individuals at clinical high risk of psychosis compared to observational cohorts: a systematic review and meta-analysis.European psychiatry : the journal of the Association of European Psychiatrists · 2021Pooled it
- Establishing a filarial clinical research platform in a resource-limited setting: Lessons and experiences from Tanzania.PLoS neglected tropical diseases · 2026Trial
- The precarious state of community engagement in African clinical trials: A systematic review of funding, workforce gaps, and the path to institutionalization.PLOS global public health · 2026Article
- Development, implementation, and evaluation of an innovative clinical trial operations training program for Africa (ClinOps).BMC medical education · 2025Article
- Regulatory approval of clinical trials: is it time to reinvent the wheel?BMJ global health · 2024Article
- Academia and industry agreement on a feasibility tool for first-time-in-human clinical trial units.Clinical and translational science · 2023Article
- Global Cancer Drug Development-A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting.JCO global oncology · 2023Article
- Addressing cancer care in low- to middle-income countries: a call for sustainable innovations and impactful research.BMC cancer · 2023Article
- Program management challenges of clinical studies: A qualitative critical assessment.Journal of family medicine and primary care · 2023Article
- Unmet Needs in Oncology Clinical Research and Treatment in Africa: Focus on Ghana.The oncologist · 2022Review
- Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials-Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop.JCO global oncology · 2022Article
- Region-specific laboratory reference intervals are important: A systematic review of the data from Africa.PLOS global public health · 2022Article
- Post-Infectious Autoimmunity in the Central (CNS) and Peripheral (PNS) Nervous Systems: An African Perspective.Frontiers in immunology · 2022Review
- Cancer Clinical Trials in Africa-An Untapped Opportunity: Recommendations From AORTIC 2019 Conference Special Interest Group in Clinical Trials.JCO global oncology · 2021Article
- Unseen and unheard: African children with cancer are consistently excluded from clinical trials.BMJ global health · 2021Article
- Oncology Clinical Trials in Africa: Emerging and Operational Issues.JCO global oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn a dramatic reversal of longstanding trends, cancer now kills more Africans than malaria. Despite Africa's growing cancer burden, individuals of African descent, notably those residing in Africa, remain drastically under-represented in cancer clinical trials. Two recent summits-the 1st All Africa Clinical Trial Summit and the Operational Strategy for Clinical Trials in Nigeria Summit-convened experts from governments, the private sector, universities, and professional societies to define the barriers to Africa's participation in multicenter clinical studies and the strategies to eliminate those impedances.
methodsThe discussions held during the two clinical trial summits were condensed into a set of 10 recommendations covering five broad categories (funding, regulation, capacity building, Africa-centric approach, and patient engagement). In this article, four programs are presented as examples of how the summits' recommendations can be put into practice to improve Africa's ability to attract clinical trials, in particular, cancer clinical trials.
resultsThese example programs all leveraged a multilateral, Africa-driven approach to building Africa's clinical trial capacity, increasing visibility of Africa's current clinical trial capabilities and priorities, improving regulatory infrastructure and enforcement on the continent, and optimizing patient and clinician engagement strategies.
conclusionThe four programs are anticipated to catalyze the involvement of more African health care sites in cancer clinical trials, enroll a greater number of African patients with cancer in those trials, and, ultimately, reverse Africa's growing cancer incidence and mortality rates. Each program acts as a blueprint for organizations-whether government, academic, or industry-seeking to address the summits' recommendations and increase Africa's contributions to and active participation in clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.